[Skip to Navigation]
December 1991

Octreotide Is Cost-effective Therapy in Diabetic Diarrhea

Author Affiliations

Cleveland, Ohio

Arch Intern Med. 1991;151(12):2469. doi:10.1001/archinte.1991.00400120103019

To the Editor. —  We wish to commend Ogbonnaya and Arem1 for their review on the pathophysiology, diagnosis, and management of diabetic diarrhea that appeared in the February 1990 issue of the ARCHIVES. Some clarifications, however, need to be made regarding the authors' discussion on the role of somatostatin and somatostatin analogues in the management of diabetic diarrhea. Referring to a letter published by Tsai et al,2 Ogbonnaya and Arem cite these authors as administering somatostatin in doses of 50 to 75 mg twice a day, while Tsai et al report administering octreotide (not somatostatin) by subcutaneous injection in doses of 50 to 75 μg (ie, micrograms [mcg vs μg], not milligrams) twice a day. A point to be made is that somatostatin and octreotide are separate compounds.3 Somatostatin has been identified as being both a 14- and 28-amino acid peptide (as well as other prosomatostatins) with

Add or change institution